Quercetin: Potentials in the prevention and therapy of disease

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 11, Issue 6, 2008, Pages 733-740

  Bischoff, Stephan C ^a  

^a UNIVERSITY OF HOHENHEIM   (Germany)

Author keywords

Endothelial function; Exercise; Flavonoids; Prevention; Quercetin

Indexed keywords

ASCORBIC ACID; CROMOGLYCATE DISODIUM; CURCUMIN; CYCLIC AMP; CYCLIC GMP; CYTOKINE; EPIMEDIUM EXTRACT; FOLIC ACID; GLYCOSIDE; ICARIIN; ICARISID; ILOPROST; NICOTINAMIDE; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN E1; QR 333; QUERCETIN; QUERCETIN AGLYCONE; QUERCETIN DERIVATIVE; QUERCETIN GLYCOSIDE; RUTOSIDE; SILDENAFIL; SORBITOL; SUGAR ALCOHOL; UNCLASSIFIED DRUG; ZAPRINAST;

ADENOMATOUS POLYP; ADJUVANT THERAPY; ALLERGIC DISEASE; ALLERGY; ANTIBACTERIAL ACTIVITY; ANTICOAGULATION; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ASTHMA; BIOLOGICAL ACTIVITY; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CATARACT; CELL CYCLE; CELL FUNCTION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COLON CANCER; COLON RESECTION; DRUG BIOAVAILABILITY; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; ENDOTHELIUM CELL; ERECTILE DYSFUNCTION; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; FOOD; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY DISEASE; INHIBITION KINETICS; NEOPLASM; NONHUMAN; OBESITY; PREVENTIVE MEDICINE; PROPHYLAXIS; REVIEW; SINGLE DRUG DOSE; THROMBOCYTE ACTIVATION;

ANIMALS; ANTIOXIDANTS; BIOLOGICAL AVAILABILITY; CYTOKINES; ENDOTHELIUM; EXERCISE; FOOD ANALYSIS; HUMANS; INTESTINAL ABSORPTION; NITRIC OXIDE; NUTRITIONAL PHYSIOLOGICAL PHENOMENA; OXIDATIVE STRESS; QUERCETIN;

EID: 55149104161     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e32831394b8     Document Type: Review

References (97)

1. Lakhanpal P, Rai DK. Quercetin: a versatile flavonoid. Internet J Med Update 2007; 2.
2. Perez-Vizcaino F, Duarte J, Andriantsitohaina R. Endothelial function and cardiovascular disease: effects of quercetin and wine polyphenols. Free Radic Res 2006; 40:1054-1065.
3. Mackraj I, Govender T, Ramesar S. The antihypertensive effects of quercetin in a salt-sensitive model of hypertension. J Cardiovasc Pharmacol 2008; 51:239-245.
4. Edwards RL, Lyon T, Litwin SE, et al. Quercetin reduces blood pressure in •• hypertensive subjects. J Nutr 2007; 137:2405-2411. This is the first pilot study showing that quercetin supplementation reduces BP in hypertensive patients.
5. Rivera L, Morón R, Sánchez M, et al. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity (Silver Spring) 2008; 16:2081 -2087. The animal study opens a new field of action of quercetin, obesity and obesity-related diseases.
6. Fang XK, Gao J, Zhu DN. Kaempferol and quercetin isolated from Euonymus alatus improve glucose uptake of 3T3-L1 cells without adipogenesis activity. Life Sci 2008; 82:615-622.
7. Graefe EU, Derendorf H, Veit M. Pharmacokinetics and bioavailability of the flavonol quercetin in humans, Int J Clin Pharmacol Ther 1999; 37:219-233.
8. Graefe EU, Willig J, Mueller S, et al. Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol 2001; 41:492-499.
9. Walle T, Otake Y, Walle UK, Wilson FA. Quercetin glucosidea are completely hydrolyzed in ileostomy patients before absorption. J Nutr 2000; 130:2658-2661.
10. Walle T, Walle UK, Halushka PV. Carbon dioxide is the major metabolite of quercetin in humans. J Nutr 2001; 131:2648-2652.
11. Conquer JA, Maiani G, Azzini E, et al. Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects. J Nutr 1998; 128:593-597.
12. Hollman PC, vd Gaag M, Mengelers MJ, et al. Absorption and disposition kinetics of the dietary antioxidant quercetin in man. Free Radic Biol Med 1996; 21:703-707.
13. Spencer JP, Kuhnle GG, Williams RJ, Rice-Evans C. Intracellular metabolism and bioactivity of quercetin and its in vivo metabolites. Biochem J 2003; 372:173-181.
14. O'Leary KA, Day AJ, Needs PW, et al. Metabolism of quercetin-7- and quercetin-3-glucuronides by an in vitro hepatic model: the role of human beta-glucuronidase, sulfotransferase, catechol-O-methyrtransferase and multiresistant protein 2 (MRP2) in flavonoid metabolism. Biochem Pharmacol 2003; 65:479-491.
15. Wu TH, Yen FL, Lin LT, et al. Preparation, physicochemical characterization, and antioxidant effects of quercetin nanoparticles. Int J Pharm 2008; 346:160-168.
16. Erlund I, Freese R, Mamiemi J, et al. Bioavailability of quercetin from berries and the diet. Nutr Cancer 2006; 54:13-17.
17. Wiczkowski W, Romaszko J, Bucinski A, et al. Quercetin from shallots (Allium cepa L. var. aggregatum) is more bioavailable than its glucosides. J Nutr 2008; 138:885-888. This study clarified that the oral bioavailability of the quercetin aglycone is good, provided that it is presented with the right cofactors such as plant maxtri components.
18. Boots AW, Haenen GR, Bast A. Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol 2008; 585:325-337.
19. Loke WM, Proudfoot JM, McKinley AJ, et al. Quercetin and its in vivo metabolites inhibit neutrophil-mediated low-density lipoprotein oxidation. J Agric Food Chem 2008; 56:3609-3615.
20. Shutenko Z, Henry Y, Pinard E, et al. Influence of the antioxidant quercetin in vivo on the level of nitric oxide determined by electron paramagnetic resonance in rat brain during global ischemia and reperfusion. Biochem Pharmacol 1999; 57:199-208.
21. Huk I, Brovkovych V, Nanobash Vili J, et al. Bioflavonoid quercetin scavenges Superoxide and increases nitric oxide concentration in ischaemia-reperfusion injury: an experimental study. Br J Surg 1998; 85:1080-1085.
22. Bindoli A, Valente M, Cavallini L. Inhibitory action of quercetin on xanthine oxidase and xanthine dehydrogenase activity. Pharmacol Res Commun 1985; 17:831-839.
23. Zhu JX, Wang Y, Kong LD, et al. Effects of Biota orientalis extract and its flavonoid constituents, quercetin and rutin on serum uric acid levels in oxonate-induced mice and xanthine dehydrogenase and xanthine oxidase activities in mouse liver. J Ethnopharmacol 2004; 93:133-140.
24. Romero M, Jiménez R, Sánchez M, et al. Quercetin inhibits vascular superoxide production induced by endothelin-1 : role of NADPH oxidase, uncoupled eNOS and PKC. Atherosclerosis 2008 [Epub ahead of print].
25. Ahn J, Lee H, Kim S, et al. The antiobesity effect of quercetin is mediated by the AMPK and MAPK signaling pathways. Biochem Biophys Res Commun 2008; 373:545-549.
26. Soundararajan R, Wishart AD, Rupasinghe HP, et al. Quercetin 3-glucoside protects neuroblastoma (SH-SY5Y) cells in vitro against oxidative damage by inducing sterol regulatory element-binding protein-2-mediated cholesterol biosynthesis. J Biol Chem 2008; 283:2231-2245. This study provides important new insights into the mechanisms of antitumor actions of quercetin.
27. Fanning MJ, Macander P, Drzewiecki G, Middleton E Jr. Quercetin inhibits anaphylactic contraction of guinea pig ileum smooth muscle, Int Arch Allergy Appl Immunol 1983; 71:371-373.
28. Pearce FL, Befus AD, Bienenstock J. Mucosal mast cells. III. Effect of quercetin and other flavonoids on antigen-induced histamine secretion from rat intestinal mast cells. J Allergy Clin Immunol 1984; 73:819-823.
29. Kimata M, Shichijo M, Miura T, et al. Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells, Clin Exp Allergy 2000; 30:501-508.
30. Kempuraj D, Castellani ML, Petrarca C, et al. Inhibitory effect of quercetin on tryptase and interleukin-6 release, and histidine decarboxylase mRNA transcription by human mast cell-1 cell line. Clin Exp Med 2006; 6:150-156.
31. Shaik YB, Castellani ML, Perrella A, et al. Role of quercetin (a natural herbal compound) in allergy and inflammation. J Biol Regul Homeost Agents 2006; 20:47-52.
32. Loke WM, Proudfoot JM, Stewart S, et al. Metabolic transformation has a profound effect on anti-inflammatory activity of flavonoids such as quercetin: lack of association between antioxidant and lipoxygenase inhibitory activity. Biochem Pharmacol 2008; 75:1045-1053.
33. Bureau G, Longpré F, Martinoli MG. Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. J Neurosci Res 2008; 86:403-410.
34. Kumazawa Y, Kawaguchi K, Takimoto H. Immunomodulating effects of flavonoids on acute and chronic inflammatory responses caused by tumor necrosis factor alpha. Curr Pharm Des 2006; 12:4271-4279.
35. Hämäläinen M, Nieminen R, Vuorela P, et al. Anti-inflammatory effects of flavonoids: genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-kappaB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-kappaB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediators Inflamm 2007:45673.
36. Lee KW, Kang NJ, Heo YS, et al. Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Res 2008; 68:946-955. This study provides important new insights into the mechanisms of antitumor actions of quercetin.
37. Ono K, Nakane H, Fukushima M, et al. Differential inhibitory effects of various flavonoids on the activities of reverse transcriptase and cellular DNA and RNA polymerases. Eur J Biochem 1990; 190:469-476.
38. Spedding G, Ratty A, Middleton E Jr. Inhibition of reverse transcriptases by flavonoids. Antiviral Res 1989; 12:99-110.
39. Neznanov N, Kondratova A, Chumakov KM, et al. Quercetinase pirin makes poliovirus replication resistant to flavonoid quercetin. DNA Cell Biol 2008; 27:191-198.
40. Davis JM, Murphy EA, McClellan JL, et al. Quercetin reduces susceptibility to influenza infection following stressful exercise. Am J Physiol Regul Integr Comp Physiol 2008; 295:R505-R509. The murine intervention study provides in-vivo evidence for an antiviral effect of quercetin, providing a first conclusive explanation why sportsmen profit from quercetin intake.
41. Gatto MT, Falcocchio S, Grippa E, et al. Antimicrobial and antilipase activity of quercetin and its C2-C16 3-O-acyl-esters. Bioorg Med Chem 2002; 10:269-272.
42. LJ M, Xu Z. Quercetin in a lotus leaves extract may be responsible for antibacterial activity. Arch Pharm Res 2008; 31:640-644.
43. Plaper A, Golob M, Hafner I, et al. Characterization of quercetin binding site on DNA gyrase. Biochem Biophys Res Commun 2003; 306:530-536.
44. González-Segovia R, Quintanar JL, Saunas E, et al. Effect of the flavonoid quercetin on inflammation and lipid peroxidation induced by Helicobacter pylori in gastric mucosa of guinea pig. J Gastroenterol 2008; 43:441-447. This animal study offers a new important usage of quercetin, which warrants further examination in humans.
45. Sheu JR, Hsiao G, Chou PH, et al. Mechanisms involved in the antiplatelet activity of rutin, a glycoside of the flavonol quercetin, in human platelets. J Agric Food Chem 2004; 52:4414-4418.
46. Hubbard GP, Stevens JM, Cicmil M, et al. Quercetin inhibits collagen-stimulated platelet activation through inhibition of multiple components of the glycoprotein VI signaling pathway. J Thromb Haemost 2003; 1:1079-1088.
47. Pignatelli P, Di Santo S, Camevale R, Violi F. The polyphenols quercetin and catechin synergize in inhibiting platelet CD40L expression. Thromb Haemost 2005; 94:888-889.
48. Fan PS, Gu ZL, Liang ZQ. Effect of quercetin on adhesion of platelets to microvascular endothelial cells in vitro. Acta Pharmacol Sin 2001; 22:857-860.
49. Ko WC, Wang HL, Lei CB, et al. Mechanisms of relaxant action of 3-O-methylquercetin in isolated guinea pig trachea. Planta Med 2002; 68:30-35.
50. Dell'Agli M, Maschi O, Galli GV, et al. Inhibition of platelet aggregation by olive oil phenols via cAMP-phosphodiesterase. Br J Nutr 2008; 99:945-951.
51. Gryglewski RJ, Korbut R, Robak J, Swies J. On the mechanism of antith-rombotic action of flavonoids. Biochem Pharmacol 1987; 36:317-322.
52. Rosenkranz S, Caglayan E, Erdmann E. Novel indications for phosphodiesterase type 5 inhibitors. Med Klin 2007; 102:617-630.
53. Palmer MJ, Bell AS, Fox DN, Brown DG. Design of second generation phosphodiesterase 5 inhibitors. Curr Top Med Chem 2007; 7:405-419.
54. Lines TC, Ono M. FRS 1000, an extract of red onion peel, strongly inhibits phosphodiesterase 5A (PDE 5A). Phytomedicine 2006; 13:236-239.
55. Xin ZC, Kim EK, Lin CS, et al. Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl 2003; 5:15-18.
56. Wang H, Liu Y, Huai Q, et al. Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development. J Biol Chem 2006; 281:21469-21479.
57. Varma SD, Mikuni I, Kinoshita JH. Flavonoids as inhibitors of lens aldose reductase. Science 1975; 188:1215-1216.
58. Bron AJ, Sparrow J, Brown NA, et al. The lens in diabetes. Eye 1993; 7:260-275.
59. Matsuda H, Morikawa T, Toguchida I, Yoshikawa M. Structural requirements of flavonoids and related compounds for aldose reductase inhibitory activity. Chem Pharm Bull (Tokyo) 2002; 50:788-795.
60. Ramana BV, Kumar W, Krishna PN, et al. Effect of quercetin on galactose-induced hyperglycaemic oxidative stress in hepatic and neuronal tissues of Wistar rats. Acta Diabetol 2006; 43:135-141.
61. van der Woude H, Ter Veld MG, Jacobs N, et al. The stimulation of cell proliferation by quercetin is mediated by the estrogen receptor. Mol Nutr Food Res 2005; 49:763-771.
62. Wong SP, Li J, Shen P, et al. Ultrasensitive cell-based bioassay for the measurement of global estrogenic activity of flavonoid mixtures revealing additive, restrictive, and enhanced actions in binary and higher order combinations. Assay Drug Dev Technol 2007; 5:355-362.
63. Schlachterman A, Valle F, Wall KM, et al. Combined resveratrol, quercetin, and catechin treatment reduces breast tumor growth in a nude mouse model. Transi Oncol 2008; 1:19-27.
64. Yamashita N, Kawanishi S. Distinct mechanisms of DNA damage in apoptosis induced by quercetin and luteolin. Free Radic Res 2000; 33:623-633.
65. Cantero G, Campanella C, Mateos S, Cortés F. Topoisomerase II inhibition and high yield of endoreduplication induced by the flavonoids luteolin and quercetin. Mutagenesis 2006; 21:321-325.
66. Aherne SA, O'Brien NM. Mechanism of protection by the flavonoids, quercetin and rutin, against tert-butylhydroperoxide- and menadione-induced DNA single strand breaks in Caco-2 cells. Free Radic Biol Med 2000; 29:507-514.
67. Murakami A, Ashida H, Terao J. Multitargeted cancer prevention by quercetin. Cancer Lett 2008 [Epub ahead of print].
68. Psahoulia FH, Drosopoulos KG, Doubravska L, et al. Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol Cancer Ther 2007; 6:2591-2599. This study provides important new insights into the mechanisms of antitumor actions of quercetin.
69. Chen W, Wang X, Zhuang J, et al. Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in nonsmall cell lung cancer cells. Carcinogenesis 2007; 28:2114-2121.
70. Kim YH, Lee YJ. TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation. J Cell Biochem 2007; 100:998-1009.
71. Brusselmans K, Vrolix R, Verhoeven G, Swinnen JV. Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J Biol Chem 2005; 280:5636-5645.
72. Xing N, Chen Y, Mitchell SH, Young CY. Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis 2001; 22:409-414.
73. Morris JD, Pramanik R, Zhang X, et al. Selenium- or quercetin-induced retardation of DNA synthesis in primary prostate cells occurs in the presence of a concomitant reduction in androgen-receptor activity. Cancer Lett 2006; 239:111-122.
74. Katske F, Shoskes DA, Sender M, et al. Treatment of interstitial cystitis with a quercetin supplement. Tech Urol 2001; 7:44-46.
75. Shoskes DA, Zeitlin SI, Shahed A, Rajfer J. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology 1999; 54:960-963.
76. Cermak R, Follmer U, Wolffram S. Dietary flavonol quercetin induces chloride secretion in rat colon. Am J Physiol 1998; 275:G1166-G1172.
77. Kim H, Kong H, Choi B, et al. Metabolic and pharmacological properties of rutin, a dietary quercetin glycoside, for treatment of inflammatory bowel disease. Pharm Res 2005; 22:1499-1509.
78. Rao CV, Vijayakumar M. Effect of quercetin, flavonoids and alpha-tocopherol, an antioxidant vitamin on experimental reflux oesophagitis in rats. Eur J Pharmacol 2008; 589:233-238.
79. Hu HL, Forsey RJ, Blades TJ, et al. Antioxidants may contribute in the fight against ageing: an in vitro model. Mech Ageing Dev 2000; 121:217-230.
80. Chopra M, Fitzsimons PE, Strain JJ, et al. Nonalcoholic red wine extract and quercetin inhibit LDL oxidation without affecting plasma antioxidant vitamin and carotenoid concentrations. Clin Chem 2000; 46:1162-1170.
81. Hubbard GP, Wolffram S, Lovegrove JA, Gibbins JM. Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans. J Thromb Haemost 2004; 2:2138-2145.
82. Hubbard GP, Wolffram S, de Vos R, et al. Ingestion of onion soup high in quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in man: a pilot study. Br J Nutr 2006; 96:482-488.
83. Mardla V, Kobzar G, Samel N. Potentiation of antiaggregating effect of prostaglandins by alpha-tocopherol and quercetin. Platelets 2004; 15:319-324.
84. Teixeira S. Bioflavonoids: proanthocyanidins and quercetin and their potential roles in treating musculoskeletal conditions. J Orthop Sports Phys Ther 2002; 32:357-363.
85. Nieman DC. Immunonutrition support for athletes. Nutr Rev 2008; 66:310-320.
86. Nieman DC, Henson DA, Davis JM, et al. Quercetin ingestion does not alter cytokine changes in athletes competing in the Western States Endurance Run. J Interferon Cytokine Res 2007; 27:1003-1011.
87. Nieman DC, Henson DA, Davis JM, et al. Quercetin's influence on exercise-induced changes in plasma cytokines and muscle and leukocyte cytokine mRNA. J Appl Physiol 2007; 103:1728-1735. This human trial shows, for the first time, in humans that quercetin supplementation improves physical power by diminishing postexercise immune alterations.
88. Henson D, Nieman D, Davis JM, et al. Post 160-km race illness rates and decreases in granulocyte respiratory burst and salivary IgA output are not countered by quercetin ingestion. Int J Sports Med 2008 [Epub ahead of print].
89. McAnulty SR, McAnulty LS, Nieman DC, et al. Chronic quercetin ingestion and exercise-induced oxidative damage and inflammation. Appl Physiol Nutr Metab 2008; 33:254-262.
90. MacRae HS, Mefferd KM. Dietary antioxidant supplementation combined with quercetin improves cycling time trial performance, Int J Sport Nutr Exerc Metab 2006; 16:405-419.
91. Hirvonen T, Virtamo J, Korhonen P, et al. Flavonol and flavone intake and the risk of cancer in male smokers (Finland). Cancer Causes Control 2001; 12:789-796.
92. Cruz-Correa M, Shoskes DA, Sanchez P, et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2006; 4:1035-1038.
93. Von Löw EC, Perabo FG, Siener R, Müller SC. Facts and fiction of phytotherapy for prostate cancer: a critical assessment of preclinical and clinical data. In Vivo 2007; 21:189-204.
94. Valensi P, Le Devehat C, Richard JL, et al. A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. J Diabetes Complications 2005; 19:247-253.
95. Okamoto T. Safety of quercetin for clinical application (review), Int J Mol Med 2005; 16:275-278.
96. Utesch D, Feige K, Dasenbrock J, et al. Evaluation of the potential in vivo genotoxicity of quercetin. Mutat Res 2008; 654:38-44.
97. Harwood M, Danielewska-Nikiel B, Borzelleca JF, et al. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 2007; 45:2179-2205. This is the first comprehensive and critical review on the safety of quercetin. Results of numerous genotoxicity and mutagenicity, short-term and long-term animal and human studies are reviewed in the context of quercetin exposure in vivo.